Previous 10 | Next 10 |
Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a global late-stage clinical messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare disease...
Dr. Markels, accomplished and experienced industry executive, most recently President of Global Vaccines at Merck, to provide strategic oversight to the Company’s vaccine franchise Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq:...
CSL Announces Closing of Global Collaboration and Licensing Agreement with Arcturus Therapeutics PR Newswire CSL to access late-stage next-generation mRNA platform technology, enabling development of vaccines for COVID-19, influenza, multi-pathogen pandemic preparedness and othe...
Summary Arcturus Therapeutics' tie-up with CSL secures financial stability for a number of years. Developing a diverse range of mRNA technology products for a variety of conditions. In a poor economic environment, biotechnology is an area not necessarily harmed by recessionary...
Baird downgraded the RNA therapeutics company Arcturus Therapeutics ( NASDAQ: ARCT ) on Thursday, citing an uncertain outlook for its recently announced partnership with Australia-based CSL Limited ( OTCPK:CSLLY ) ( OTC:CMHXF ) and seeing a delay in a key development pro...
Arcturus Therapeutics Holdings Inc. (ARCT) Q3 2022 Results Conference Call November 09, 2022 04:30 PM ET Company Participants Kyle Gutsadt - Investor Relations Joseph Payne - President and Chief Executive Officer Andrew Sassine - Chief Financial Officer Padma...
Arcturus Therapeutics press release ( NASDAQ: ARCT ): Q3 GAAP EPS of -$1.33 beats by $0.44 . Revenue of $13.4M (+449.2% Y/Y) beats by $9.31M . The Company’s cash balance totaled $237.7M as of September 30, 2022, compared to a cash balance of $370.5M at D...
Entered into global partnership with CSL to develop and commercialize self-amplifying mRNA vaccines targeting COVID-19, influenza, additional pathogens, and pandemic preparedness with $200 million upfront and up to $4.3 billion in potential development and commercial milestones ...
Arcturus Therapeutics Holdings Inc. (the “Company,” “Arcturus,” Nasdaq: ARCT), a global, late-stage clinical messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory r...
Citi has upgraded Arcturus Therapeutics to buy from neutral saying that the company's recent strategic collaboration with CSL Sequirus validates its mRNA platform. The firm has a $35 price target (~61% upside based on Wednesday's close). Analyst Yigal Nochomovitz noted tha...
News, Short Squeeze, Breakout and More Instantly...
Arcturus Therapeutics Ltd. Company Name:
ARCT Stock Symbol:
NASDAQ Market:
Arcturus Therapeutics Ltd. Website:
Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a global messenger RNA medicines company focused on the development of infectious disease vaccines and medicines to treat unmet medical needs within liver and respiratory rare diseases, toda...
2024-07-02 10:15:03 ET Piper Sandler analyst issues OVERWEIGHT recommendation for ARCT on July 2, 2024 08:19AM ET. The previous analyst recommendation was Overweight. ARCT was trading at $23.66 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...
ARCT-810 Phase 2 study completed enrollment at 0.3 mg/kg dose level in Europe with data expected later this year ARCT-810 to expand Phase 2 clinical program in the U.S. to enroll patients with more severe disease ARCT-032 IND for Phase 2 multiple ascending dose study to be submitt...